MARKET

VBIV

VBIV

VBI Vaccines
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.020
+0.100
+3.42%
After Hours: 3.020 0 0.00% 16:41 05/17 EDT
OPEN
2.868
PREV CLOSE
2.920
HIGH
3.030
LOW
2.820
VOLUME
1.78M
TURNOVER
--
52 WEEK HIGH
6.93
52 WEEK LOW
1.850
MARKET CAP
767.67M
P/E (TTM)
-12.9781
1D
5D
1M
3M
1Y
5Y
VBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious Diseases
Benzinga · 5d ago
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBIs Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that results from the pivotal Phase 3 study, PROTECT, of VBI’s prophylactic 3-antigen h...
Business Wire · 5d ago
BRIEF-VBI Vaccines Announces Publication Of Results From Pivotal Phase 3 Study Of Its Prophylactic 3-Antigen Hepatitis B Vaccine Candidate In The Lancet Infectious Diseases
reuters.com · 5d ago
VBI Vaccines shares rise on late-stage hepatitis B vaccine study data
VBI Vaccines (VBIV) shares rise more than 2% during premarket trading after results from the company's pivotal Phase 3 study of prophylactic 3-antigen hepatitis B ((HBV)) vaccine candidate in adults were published in
Seekingalpha · 5d ago
VBI Vaccines (VBIV) Receives a Buy from BMO Capital
BMO Capital analyst Do Kim maintained a Buy rating on VBI Vaccines (VBIV) today and set a price target of $6.00. The company's shares closed last Tuesday
SmarterAnalyst · 6d ago
VBI Vaccines (VBIV) Gets a Buy Rating from Raymond James
In a report released yesterday, Steven Seedhouse from Raymond James maintained a Buy rating on VBI Vaccines (VBIV), with a price target of $9.00. The
SmarterAnalyst · 6d ago
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Lags Revenue Estimates
Zacks.com · 05/10 13:15
VBI Vaccines Q1 EPS $(0.07) Down From $(0.05) YoY, Sales $300.00K Down From $415.00K YoY
VBI Vaccines (NASDAQ:VBIV) reported quarterly losses of $(0.07) per share. This is a 40 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $300.00 thousand in sales
Benzinga · 05/10 13:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VBIV. Analyze the recent business situations of VBI Vaccines through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VBIV stock price target is 7.50 with a high estimate of 9.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 156
Institutional Holdings: 134.07M
% Owned: 52.74%
Shares Outstanding: 254.20M
TypeInstitutionsShares
Increased
49
8.01M
New
34
3.48M
Decreased
25
2.73M
Sold Out
22
13.37M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Independent Director
Steven Gillis
President/Chief Executive Officer/Director
Jeffrey Baxter
Chief Financial Officer/Director
Christopher McNulty
Chief Scientific Officer
David Anderson
General Manager
Avi Mazaltov
Other
Nell Beattie
Other
Francisco Diaz-Mitoma
Independent Director
Damian Braga
Independent Director
Joanne Cordeiro
Independent Director
Blaine Mckee
Independent Director
Michel Wilde
No Data
About VBIV
VBI Vaccines Inc. is a development-stage biotechnology company. The Company's principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company's subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).

Webull offers kinds of VBI Vaccines Inc stock information, including NASDAQ:VBIV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VBIV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VBIV stock methods without spending real money on the virtual paper trading platform.